|
WO2020162582A1
|
|
Methods of treating non-virally-induced cancers
|
|
WO2020162471A1
|
|
Pyridone derivative
|
|
WO2020149282A1
|
|
Use of omiganan in the treatment of rosacea
|
|
WO2020161771A1
|
|
Skin composition
|
|
WO2019151287A1
|
|
External composition for skin
|
|
WO2019151285A1
|
|
Skin composition for external use
|
|
WO2019151286A1
|
|
Topical dermatological composition
|
|
WO2019131929A1
|
|
Anti-inflammatory agent
|
|
WO2019082873A1
|
|
Coating-forming topical agent
|
|
US2020360471A1
|
|
Methods of treating and preventing viral infections
|
|
WO2020021670A1
|
|
Liquid topical preparation
|
|
WO2018230733A1
|
|
External preparation for skin
|
|
MX2019005372A
|
|
Medical skin external preparation.
|
|
JP2017200911A
|
|
Antimicrobial agent
|
|
WO2017111107A1
|
|
Transfer-printing method for polyester-based fibrous materials
|
|
US2018177879A1
|
|
External preparation for transdermal administration
|
|
WO2016136925A1
|
|
Composition for skin
|
|
EP3257512A1
|
|
External preparation comprising pyridonecarboxylic acid derivative
|
|
WO2017068673A1
|
|
Pharmaceutical composition for skin
|
|
WO2016061328A1
|
|
Topical composition
|
